| Literature DB >> 27792008 |
Abstract
This article discusses the patent strategy underlying the world's best selling drug, AbbVie's Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. This article is the first part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics.Entities:
Keywords: Adalimumab; Humira; biosimilars; dosage; formulation; patent
Mesh：
Substances：
Year: 2017 PMID： 27792008 DOI： 10.3233/HAB-160300
Source DB: PubMed Journal: Hum Antibodies ISSN： 1093-2607